Package Leaflet: Information for the User
EMEND 125mg powder for oral suspension
aprepitant
Read all of this leaflet carefully before you start giving this medicine to your child because it contains important information for them.This leaflet has been written for the parent or caregiver who will be giving this medicine to the child. Read this information carefully.
Contents of the pack
EMEND contains the active substance aprepitant. It belongs to a group of medicines called 'neurokinin 1 (NK1) receptor antagonists'. The brain has a specific area that controls nausea and vomiting. EMEND works by blocking the signals to this area, reducing nausea and vomiting. The oral suspension is used in children from 6 months to less than 12 years of age, in combinationwith other medicinesto prevent nausea and vomiting caused by a type of chemotherapy (cancer treatment) that induces strong and moderate nausea and vomiting (such as cisplatin, cyclophosphamide, doxorubicin, or epirubicin).
Do not give EMEND
Do not give this medicine if your child is in any of the above situations and inform your child's doctor if they are taking any of the medicines mentioned above. This is because their treatment may need to be modified before starting treatment with this medicine. If you are not sure, consult your doctor, pharmacist, or nurse before giving this medicine.
Warnings and precautions
Consult your doctor, pharmacist, or nurse before giving this medicine to your child.
Liver problems
If your child has liver problems, consult your doctor before starting treatment with EMEND. This is because the liver is important for removing the medicine from the body. Your doctor may need to monitor your child's liver condition during treatment.
Children and adolescents
Do not give EMEND oral suspension to children under 6 months of age or weighing less than 6 kg or to adolescents between 12 and 18 years of age, as the oral suspension has not been studied in this population.
Other medicines and EMEND
Tell your doctor, pharmacist, or nurse if your child is taking, has recently taken, or might take any other medicines. This is because EMEND may affect the activity of other medicines during and after treatment with EMEND. Also, some medicines may affect how this medicine works.
Do not give EMEND and inform your doctor or pharmacist if your child is taking any of the following medicines (see also 'Do not give EMEND'). This is because their treatment may need to be modified before starting EMEND:
Do not give this medicine and consult your doctor or pharmacist if any of the above applies to your child (or if you are unsure).
Inform your doctor, pharmacist, or nurse if your child is taking any of the following medicines:
Inform your doctor, pharmacist, or nurse before giving this medicine to your child if any of the above applies to them (or if you are unsure).
Pregnancy and breastfeeding
Do not use this medicine during pregnancy and breastfeeding unless clearly necessary.
For information related to pregnancy, breastfeeding, and contraception, ask your doctor for advice.
Driving and using machines
It should be taken into account that some people may feel dizzy and sleepy after taking EMEND. If your child feels dizzy or sleepy, they should not ride a bike or use tools or machines.
EMEND contains sucrose and lactose
The oral suspension contains sucrose and lactose. If your doctor has told you that your child has an intolerance to some sugars, consult them before giving this medicine to your child.
EMEND contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per dose; this is essentially 'sodium-free'.
Healthcare professionals: See the end of this leaflet for instructions for healthcare professionals on preparing the oral suspension. It tells you how to prepare the dose of EMEND as an oral suspension.
Parents and caregivers: Follow the administration instructions for this medicine exactly as indicated for your child by their doctor, pharmacist, or nurse. If you are unsure, consult your child's doctor, pharmacist, or nurse again.
It is very important that this medicine is given exactly as indicated below.
For each dose of EMEND, you will have a pre-loaded oral dispenser that contains the prescribed dose for your child.
Keep the oral dispenser in the refrigerator (between 2 °C and 8 °C) until you give the medicine to your child.
Use this medicine during the 2 days following receipt of the medicine from the healthcare professional.
Before administration, the medicine can be stored at room temperature (not above 30 °C) for up to 3 hours.
The color of the medicine in the oral dispenser may be different shades of pink (from light pink to dark pink). This is normal and the medicine can be used.
If your child cannot take the full dose, call your child's healthcare professional.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
How much to give
When to give
Day 1:
Day 2 and Day 3:
EMEND can be given with or without food.
Always give this medicine with other medicines to prevent nausea and vomiting. After treatment with EMEND, your doctor may advise your child to continue taking other medicines to prevent nausea and vomiting, such as:
If you are unsure, ask your doctor, pharmacist, or nurse.
If you give more EMEND than you should
Do not give your child more medicine than prescribed by the doctor. If you give your child more than they should, contact your doctor immediately.
If you forget to give EMEND
If your child misses a dose of this medicine, consult your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
Stop giving this medicine and seek medical help immediately if you or your child notice any of the following serious side effects – your child may need urgent medical treatment:
Stop giving this medicine and seek medical help immediately if you notice any of the serious side effects listed above.
Other side effects
Tell your doctor, pharmacist, or nurse if you or your child notice any of the following side effects:
Common:may affect up to 1 in 10 people
Uncommon:may affect up to 1 in 100 people
Rare:may affect up to 1 in 1,000 people
Reporting of side effects
If your child experiences any side effects, consult your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Before reconstitution:
EMEND will generally be stored by healthcare professionals. If needed, the storage details are as follows:
Do not give this medicine to your child after the expiry date which is stated on the carton and blister after EXP. The expiry date is the last day of the month stated.
This medicine does not require any special storage temperature.
Keep in the original packaging to protect from moisture.
After reconstitution:
Before administration, the oral suspension can be stored at room temperature (not above 30 °C) for up to 3 hours. It can also be stored in the refrigerator (between 2 °C and 8 °C) for up to 72 hours.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of EMEND
Appearance and Container Contents
The powder for oral suspension is a pink to light pink powder in a single-use sachet.
Single-use box
The box contains a sachet, a 1 ml oral dispenser, and a 5 ml oral dispenser (made of polypropylene with a plunger topped with a silicone ring), a cap, and a mixing cup (made of polypropylene).
Marketing Authorization Holder and Manufacturer
Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem Netherlands |
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Belgium/België/Belgien MSD Belgium Tel: +32(0)27766211 dpoc_belux@msd.com | Lithuania UAB Merck Sharp & Dohme Tel: +370 5 2780 247 dpoc_lithuania@msd.com |
Luxembourg/Luxemburg MSD Belgium Tel: +32(0)27766211 dpoc_belux@msd.com | |
Czech Republic Merck Sharp & Dohme s.r.o. Tel: +420 233 010 111 dpoc_czechslovak@merck.com | Hungary MSD Pharma Hungary Kft. Tel: +36 1 888 5300 hungary_msd@merck.com |
Denmark MSD Danmark ApS Tel: +45 4482 4000 dkmail@msd.com | Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com |
Germany MSD Sharp & Dohme GmbH Tel: +49 (0)89 20 300 4500 medinfo@msd.de | Netherlands Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) medicalinfo.nl@merck.com |
Estonia Merck Sharp & Dohme OÜ Tel: +372 614 4200 dpoc.estonia@msd.com | Norway MSD (Norge) AS Tel: +47 32 20 73 00 medinfo.norway@msd.com |
Greece MSD Α.Φ.Ε.Ε. Tel: +30 210 98 97 300 dpoc_greece@merck.com | Austria Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0)1 26 044 dpoc_austria@merck.com |
Spain Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 msd_info@msd.com | Poland MSD Polska Sp. z o.o. Tel: +48 22 549 51 00 msdpolska@merck.com |
France MSD France Tel: +33 (0)1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 inform_pt@merck.com |
Croatia Merck Sharp & Dohme d.o.o. Tel: +385 1 6611 333 croatia_info@merck.com | Romania Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 msdromania@merck.com |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 medinfo_ireland@msd.com | Slovenia Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386 1 520 4201 msd_slovenia@merck.com |
Iceland Vistor ehf. Tel: +354 535 7000 | Slovak Republic Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 dpoc_czechslovak@merck.com |
Italy MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) dpoc.italy@msd.com | Finland MSD Finland Oy Tel: +358 (0)9 804 650 info@msd.fi |
Cyprus Merck Sharp & Dohme Cyprus Limited Tel: 8000 6733 (+357 22866700) cyprus_info@merck.com | Sweden Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 medicinskinfo@msd.com |
Latvia SIA Merck Sharp & Dohme Latvija Tel: +371 67025300 dpoc.latvia@msd.com |
Date of Last Revision of this Leaflet:
Other Sources of Information
Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu.
--------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Instructions for healthcare professionals on the preparation of the oral suspension
Each box of EMEND contains a sachet with the powder for oral suspension, a 1 ml oral dispenser, a 5 ml oral dispenser, a cap, and a mixing cup. | |||
| |||
Check that there is no air in the oral dispenser (if there is air, remove it). | |||
| |||
| |||
Hold the EMEND powder for oral suspension sachet upright and shake the contents down before opening the sachet.
| |||
To avoid foam, do not shake the mixing cup. The mixture will be a cloudy pink to light pink color. | |||
| |||
Check that there is no air in the oral dispenser (if there is air, remove it). Check that the oral dispenser contains the prescribed dose. | |||
Day 1 | Day 2 | Day 3 | |
EMEND oral suspension 25 mg/ml | 3 mg/kg orally Maximum dose 125 mg | 2 mg/kg orally Maximum dose 80 mg | 2 mg/kg orally Maximum dose 80 mg |
| |||
Discard any leftover suspension and materials that have come into contact with it. The disposal of unused medicine and all materials that have come into contact with it will be carried out in accordance with local regulations. |